Patents Issued in December 17, 2024
-
Patent number: 12168643Abstract: The present disclosure relates to compounds of Formula I: suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the CIC-1 ion channel.Type: GrantFiled: June 19, 2020Date of Patent: December 17, 2024Assignee: NMD PHARMA A/SInventors: Nicholas Kelly, Lars J.S. Knutsen, Daniel Paul Cotton
-
Patent number: 12168644Abstract: The present invention relates to a method for preparing 2-alkoxy-4-amino-5-methylpyridines of the formula (I) and/or 2-alkoxy-4-alkylamino-5-methylpyridines of the formula (II) from the corresponding 2-haloaminopyridines and the appropriate alcohols in the presence of base, and to the compounds resulting therefrom.Type: GrantFiled: December 20, 2019Date of Patent: December 17, 2024Assignee: Saltigo GmbHInventor: Karsten von dem Bruch
-
Patent number: 12168645Abstract: Provided are a phenanthroimidazole derivative, and a preparation method therefor, and an application thereof. The phenanthroimidazole derivative has a structural formula as shown in Formula (I), R being an electron donor group, wherein by taking a phenanthroimidazole group containing a trifluoromethyl phenyl group as an electron acceptor, and in virtue of the properties of the specific electron donor group R, the phenanthroimidazole derivative containing a light-absorbing photosensitive group of a series D-?-A structure is synthesized, and can be used as a photoinitiator, which is used in the technical field of UV light-curing systems or 3D printing.Type: GrantFiled: July 30, 2021Date of Patent: December 17, 2024Assignee: GUANGDONG UNIVERSITY OF TECHNOLOGYInventors: Yanping Huo, Yudong Wen, Hongping Xiang, Shaomin Ji, Wencheng Chen, Jiye Luo, Liang Gao, Jingwei Zhao
-
Patent number: 12168646Abstract: The present invention relates to pharmaceutical compounds of Formula (I): as further described herein, and pharmaceutical compositions containing such compounds, as well as methods of using these compounds to modulate the activity of aryl hydrocarbon receptor (AhR) and to treat conditions comprising inflammation inside the intestinal tract and certain disorders of the central nervous system affected by the gut-brain axis, including IBD, ulcerative colitis, Crohn's disease, Huntington's disease, and multiple sclerosis.Type: GrantFiled: February 5, 2024Date of Patent: December 17, 2024Assignee: NEXYS THERAPEUTICS, INC.Inventors: Tom Yao-Hsiang Wu, Qihui Jin
-
Patent number: 12168647Abstract: Described herein are compounds according to Formula (I) wherein Rf is a perfluorinated divalent group comprising 2 to 12 carbon atoms; and Z is selected from —CH?CH2, and —CH2CH?CH. A method of making the compound from a functionalized vinyl ether and ammonia is disclosed. In one embodiment, the functionalized triazine-containing compound is used in the polymerization of a fluoropolymer. In another embodiment, the functionalized triazine-containing compound is used in a curable fluoropolymer composition and cured to form articles.Type: GrantFiled: June 22, 2020Date of Patent: December 17, 2024Assignee: 3M Innovative Properties CompanyInventors: Michael H. Mitchell, Tatsuo Fukushi, Miguel A. Guerra, Zai-Ming Qiu, Justin T. Roop
-
Patent number: 12168648Abstract: Provided herein are opioid receptor modulators and pharmaceutical compositions comprising said compounds.Type: GrantFiled: February 13, 2023Date of Patent: December 17, 2024Assignee: EPIODYNE, INC.Inventors: Julio Cesar Medina, Alok Nerurkar, Corinne Sadlowski, Frederick Seidl, Heng Cheng, Jason Duquette, John Lee, Martin Holan, Pingyu Ding, Xiaodong Wang, Tien Widjaja, Thomas Nguyen, Ulhas Bhatt, Yihong Li, Zhi-liang Wei
-
Patent number: 12168649Abstract: The present invention relates to a process for the production of chromanol and 2-methyl-1,4-naphthoquinone derivatives, more specifically to a process for preparing a compound of the general formula (I) or (II) wherein the variables are as defined in the claims and the description.Type: GrantFiled: August 16, 2019Date of Patent: December 17, 2024Assignee: BASF SEInventors: Melanie Weingarten, Wolfgang Siegel, Michael Puhl
-
Crystalline forms of 3-(5-(2-hydroxy-2-methylpropoxy)-6-methylpyrazin-2-yl)-1H-indole-7-carbonitrile
Patent number: 12168650Abstract: This disclosure provides crystalline forms of an androgen receptor modulator, and methods of making and using these forms.Type: GrantFiled: January 13, 2023Date of Patent: December 17, 2024Assignee: NIDO BIOSCIENCES, INC.Inventors: Bakary-Barry Toure, Magnus Ronn -
Patent number: 12168651Abstract: An 9-(6-flouro-2-hydroxypyridin-3-yl)-10-(2-hydroxyethyl)-3,6-diphenyl-3,4,6,7,9,10-hexahydroacridine1,8(2H,5H)-dione compound, its synthesis, and its use as an antimicrobial agent.Type: GrantFiled: January 29, 2024Date of Patent: December 17, 2024Assignee: KING FAISAL UNIVERSITYInventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed
-
Patent number: 12168652Abstract: Disclosed herein are carborane derivatives of Formula I or Formula V, or a pharmaceutically acceptable salt thereof, for use as neuromuscular blocking agents. The carborane is substituted with two cationic functional groups selected from amines that form ammonium cations, ethers and/or alcohols that form oxonium cations, sulfides and/or thiols that form sulfonium cations, and phosphanes and/or phosphines that form phosphonium cations.Type: GrantFiled: March 27, 2019Date of Patent: December 17, 2024Assignee: The Curators of the University of MissouriInventors: George R. Kracke, Lalit N. Goswami, Marion F Hawthorne, Satish S. Jalisatgi
-
Patent number: 12168653Abstract: The present invention relates to compounds of formula (I): (I) wherein Q is selected from O or S; R1 is an optionally substituted hydrocarbyl group which may optionally include one or more heteroatoms N, O or S in its carbon skeleton, provided that the hydrocarbyl group includes at least one heteroatom N, O or S in its carbon skeleton or is substituted with a substituent comprising at least one heteroatom N, O or S, and provided that the atom of R1 which is attached to the sulfur atom of the remainder of the molecule is not a ring atom of a cyclic group; R2 is an ?,??-substituted cyclic group which may optionally be further substituted; R3 and R4 are each independently hydrogen, halogen, —OH, —NH2, —CN, —R5, —OR5, —NHRs or —N(R5)2; or R3 and R4 together with the carbon atom to which they are attached may form a 3- to 7-membered saturated or unsaturated, optionally substituted cyclic group; and R5 is independently optionally substituted C1-C4 alkyl.Type: GrantFiled: March 1, 2019Date of Patent: December 17, 2024Assignee: INFLAZOME LIMITEDInventors: Matthew Cooper, David Miller, Jimmy Van Wiltenburg, Jonathan Shannon, Stephen St-Gallay
-
Patent number: 12168654Abstract: The present invention discloses a pyrimidine derivative containing one deuterium atom, a preparation process thereof and a use thereof. It is demonstrated through in vivo and in vitro animal experiments that the antitumor activity of the pyrimidine derivative containing one deuterium atom provided in the disclosure is significantly superior to that of the positive drug Tepotinib, and the preparation process is simple and low in cost.Type: GrantFiled: January 25, 2021Date of Patent: December 17, 2024Assignees: Guangdong Lewwin Pharmaceutical Research Institute Co., Ltd., Guangdong CS-Lewwin Drug Research Co., Ltd.Inventors: Xingshu Li, Xinzi Chen, Wei Yang, Jianmin Guo
-
Patent number: 12168655Abstract: The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are APJ agonists which may be used as medicaments.Type: GrantFiled: June 9, 2022Date of Patent: December 17, 2024Assignee: Bristol-Myers Squibb CompanyInventors: Wei Meng, Hannguang J. Chao, Heather Finlay, R. Michael Lawrence, Michael C. Myers
-
Patent number: 12168656Abstract: A process for making (E)-7-(4-((5-(2-chlorobenzylideneamino)-2-thioxo-1,3,4-thiadiazol-3(2H)-yl)methyl)piperazin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid compound The process including: stirring a solution of 5-(2-chlorobenzylideneamino)-1,3,4-thiadiazole-2(3H)-thione and formaldehyde in ethanol to obtain a reaction mixture; adding ciprofloxacin HCl and triethylamine to the reaction mixture and stirring with reflux; cooling the reaction mixture at room temperature to obtain a solid; and obtaining the 7-(4-((5-(2-chlorobenzylideneamino)-2-thioxo-1,3,4-thiadiazol-3(2H)-yl)methyl)piperazin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid compound. Its use as an anticancer and/or anti-inflammatory agent.Type: GrantFiled: February 6, 2024Date of Patent: December 17, 2024Assignee: KING FAISAL UNIVERSITYInventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
-
Patent number: 12168657Abstract: The present disclosure relates to inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein.Type: GrantFiled: November 9, 2022Date of Patent: December 17, 2024Assignee: Ventus Therapeutics U.S., Inc.Inventors: Stéphane Dorich, Amandine Chefson
-
Patent number: 12168658Abstract: Provided are compounds, compositions and methods for inhibiting fascin activity or treating a condition or disorder mediated by fascin activity in a subject in need thereof.Type: GrantFiled: December 21, 2023Date of Patent: December 17, 2024Assignees: NOVITA PHARMACEUTICALS, INC., CORNELL UNIVERSITYInventors: Xin-Yun Huang, Christy Young Shue
-
Patent number: 12168659Abstract: A thioamide derivative of formula (I) and a preparation method thereof: An application of the thioamide derivative, or an isomer, a pharmaceutically-acceptable salt, or a prodrug molecule thereof in the preparation of a drug for the treatment of cancer is also provided. The thioamide derivative is a new compound with high antitumor activity, and can be used for antitumor therapy alone or in combination with other drugs.Type: GrantFiled: April 25, 2024Date of Patent: December 17, 2024Assignee: Yunbaiyao Zhengwu Science and Technology (Shanghai) Co., Ltd.Inventors: Zhengwu Shen, Bin Deng, Mengqi Zhang, Hongzhu Bian
-
Patent number: 12168660Abstract: The present disclosure relates to derivatives (e.g., hydroxyl, keto, glucuronide, sulfonic acid, and deuterated) of a Fibroblast Growth Factor Receptors (FGFR) inhibitor, including methods of preparation thereof, and intermediates in the preparation thereof, which are useful in the treatment of FGFR mediated disease such as cancer.Type: GrantFiled: July 22, 2022Date of Patent: December 17, 2024Assignee: Incyte CorporationInventors: Ming Tao, Jason Boer
-
Patent number: 12168661Abstract: A series of novel donor-acceptor type TADF luminogens have been designed with the aim of developing stable OLEDs with enhanced operational stability and improved color purity. These materials can be utilized in full color displays and lighting applications.Type: GrantFiled: February 18, 2021Date of Patent: December 17, 2024Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITYInventors: Jian Li, Xinqiang Tan
-
Patent number: 12168662Abstract: Novel pyrido[4?,3?:4,5]pyrrolo[2,3-c][2,7]naphthyridine compounds, a method of synthesizing said compounds, a pharmaceutical composition comprising said compounds and a suitable carrier, and a method of using the compounds. The pyrido[4?,3?:4,5]pyrrolo[2,3-c][2,7]naphthyridine compounds, identified as CK2 inhibitors, are useful as anticancer and/or antitumor agents, and as agents for treating other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and other types of diseases such as diabetes, viral infection, neurodegenerative diseases.Type: GrantFiled: December 15, 2023Date of Patent: December 17, 2024Assignee: KING FAISAL UNIVERSITYInventors: Christophe Tratrat, Michelyne Haroun
-
Patent number: 12168663Abstract: The present invention provides novel compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating and/or preventing proliferative diseases (e.g., cancers (e.g., leukemia, acute lymphoblastic leukemia, lymphoma, Burkitt's lymphoma, melanoma, multiple myeloma, breast cancer, Ewing's sarcoma, osteosarcoma, brain cancer, neuroblastoma, lung cancer, colorectal cancer), benign neoplasms, diseases associated with angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as a cyclin-dependent kinase (CDK) (e.g.Type: GrantFiled: September 28, 2020Date of Patent: December 17, 2024Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Nathanael S. Gray, Yanke Liang, Tinghu Zhang, Nicholas Paul Kwiatkowski
-
Patent number: 12168664Abstract: The present invention provides a compound having the structure: wherein R1, R2, R3, R4, and R5 are each independently H, halogen, CF3, C1-C4 alkyl, aryl or heteroaryl; X is N or CR6, wherein R6 is H, OH, or halogen; A is absent or present, and when present is B has the structure: or a pharmaceutically acceptable salt thereof.Type: GrantFiled: October 30, 2020Date of Patent: December 17, 2024Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Konstantin Petrukhin, Kirsten Alison Rinderspacher, Shi-Xian Deng, Andras Varadi, Boglarka Racz, Peter Bernstein, Patricia C. Weber, Donald W. Landry, Andrew S. Wasmuth
-
Patent number: 12168665Abstract: Provided are compounds of formula (I): or a cosmeceutically acceptable or pharmaceutically acceptable salts thereof. Additionally provided are pharmaceutical and/or cosmeceutical compositions and formulations comprising the compounds and/or the cosmeceutically acceptable or pharmaceutically acceptable salts thereof, therapeutic and/or cosmetic methods using same for modulating (e.g., inhibiting) CREB binding protein (CBP)/?-catenin mediated signaling in treating skin related diseases, conditions or disorders (e.g., dermatitis, psoriasis, scarring, alopecia, etc.) mediated by aberrant CBP/?-catenin signaling, and cosmetic methods for treating skin conditions (e.g., aging, etc.) mediated by aberrant CBP/?-catenin signaling.Type: GrantFiled: April 27, 2023Date of Patent: December 17, 2024Assignee: Genesis Molecular Technologies, Inc.Inventor: Fuqiang Ruan
-
Patent number: 12168666Abstract: An advantageous isolated morphic form of trilaciclib which is 2?-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7?,8?-dihydro-6?H-spiro[cyclohexane-1,9?-pyrazino[1?,2?:1,5]pyrrolo[2,3-d]pyrimidin]-6?-one, for example in the form of a di-hydrochloride salt or a dihydrochloride, dihydrate.Type: GrantFiled: April 21, 2021Date of Patent: December 17, 2024Assignee: G1 Therapeutics, Inc.Inventors: Stephen Schneider, Alexander Smith, Hannah S. White, Jay Copeland Strum, Jaroslaw Mazurek
-
Patent number: 12168667Abstract: The present application relates to an anti-tumor compound and a preparation method and use thereof, and in particular to a compound or a tautomer, a mesomer, a racemate, an enantiomer or a diastereoisomer thereof, or a mixture thereof, or a pharmaceutically acceptable salt thereof, and a preparation method and use thereof.Type: GrantFiled: November 10, 2023Date of Patent: December 17, 2024Assignee: DUALITY BIOLOGICS (SUZHOU) CO., LTD.Inventors: Yu Zhang, Zhongyuan Zhu, Haiqing Hua, Bing Li, Jian Li, Shengchao Lin, Xi Li, Hongxia Shen
-
Patent number: 12168668Abstract: Provided herein are compounds that inhibit the phosphorylation of MAPK and thus are useful in compositions and methods for treating cancer and inflammatory disease.Type: GrantFiled: October 28, 2022Date of Patent: December 17, 2024Assignee: SHY Therapeutics LLCInventors: Yaron R. Hadari, Luca Carta, Michael Schmertzler, Theresa M. Williams, Charles H. Reynolds
-
Patent number: 12168670Abstract: Embodiments of the present invention provide a method, comprising obtaining a lecithin-containing material, in some aspects derived from a crude refining stream, comprising 20-80 wt % acetone insoluble matter, 1-30 wt % free fatty acid, and less than 10 wt % water, adding a fatty acid or carboxylic source to the lecithin-containing material to obtain a lecithin fatty acid blend or lecithin carboxylic acid blend and incorporating the blend into asphalt or oil field applications.Type: GrantFiled: October 19, 2023Date of Patent: December 17, 2024Assignee: CARGILL, INCORPORATEDInventors: Todd L. Kurth, Suzanne Stauduhar, Hassan Ali Tabatabaee
-
Patent number: 12168671Abstract: Provided are phosphonopyrazole-based phosphohistidine analogs that are useful as haptens for the preparation of immunogens, immunogens that include these haptens linked to carrier molecules, antibodies thereto and uses of these antibodies, haptens, immunogens and phosphohistidine analogs.Type: GrantFiled: March 29, 2022Date of Patent: December 17, 2024Assignee: THE TRUSTEES OF PRINCETON UNIVERSITYInventors: Tom W. Muir, Rob C. Oslund, Jung-Min Kee
-
Patent number: 12168672Abstract: Processed lignin comprising the elements carbon (C), hydrogen (H) and oxygen (O) in the following amounts: C in an amount of between 60 and 85% by weight, H in an amount of between 3.0 and 6.0% by weight, O in an amount of between 10 and 29% by weight, wherein the weight ratio C/H is at least 12.5, the ratio C/O is at least 2.5, the processed lignin comprises less than 0.1% by weight of total CI, a sulphur content below 1 g/kg, and a moisture content less than 3% by weight. A process to prepare the processed lignin comprising subjecting particles comprising lignin and cellulose and optionally hemicellulose to acidic hydrolysis using hydrochloric acid of at least 35%, subjecting the obtained residue to a high temperature treatment of between 300 and 500° C. under inert gaseous atmosphere to a total CI level of below 0.1% by weight, after drying.Type: GrantFiled: June 8, 2020Date of Patent: December 17, 2024Assignee: Avantium Knowledge Centre B.V.Inventors: Anna Louise Jongerius, Scott Henry Russell, Kay Jochem Damen, Benjamin McKay
-
Patent number: 12168673Abstract: Prodrugs of nicotinic acid which include ribosyl groups are provided. The compounds and pharmaceutical compositions thereof may be used to treat or prevent to treat or prevent a variety of medical disorders, which are characterized by mitochondrial dysfunction such as, for example, metabolic disorders, cardiovascular disorders, cerebrovascular disorders, liver disorders, kidney disorders or muscle disorders.Type: GrantFiled: March 2, 2023Date of Patent: December 17, 2024Assignee: Mitopower, Inc.Inventors: G. Mani Subramanian, Gangadhara Ganapati, Manoj Chandrasinhji Desai, Nikhil Saji Zachariah, Ajay Kumar K S, Gautham Tumkur Pranesh
-
Patent number: 12168674Abstract: The present disclosure provides reagent compounds, reactive biopolymeric compounds, and methods of making and using these materials for the rapid and efficient synthesis and purification of biopolymeric compounds at low cost. The materials and methods yield highly pure synthetic biopolymeric compounds, including synthetic oligonucleotides and polypeptides, and reduce or eliminate the need for toxic solvents in the synthetic process.Type: GrantFiled: December 8, 2023Date of Patent: December 17, 2024Assignee: Oligo Foundry, Inc.Inventors: David A. Schwartz, Jimmy H. Williams
-
Patent number: 12168675Abstract: The invention features modified alphavirus or flavivirus virus-like particles (VLPs). The invention provides methods, compositions, and kits featuring the modified VLPs. The invention also features methods for enhancing production of modified VLPs for use in the prevention or treatment of alphavirus and flavivirus-mediated diseases. The invention also provides methods for delivering agents to a cell using the modified VLPs.Type: GrantFiled: June 7, 2023Date of Patent: December 17, 2024Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Gary J. Nabel, Srinivas Rao, Wataru Akahata
-
Patent number: 12168676Abstract: The disclosure provides therapeutic peptides and pharmaceutical compositions comprising the peptides, which have utility in treating various human diseases. In particular aspects, the disclosed therapeutic peptides are useful as immunotherapeutics for modulating regulatory and effector molecules of the mammalian immune system to mitigate disease.Type: GrantFiled: January 6, 2020Date of Patent: December 17, 2024Assignee: Genevive, Inc.Inventors: Yuliya Katlinskaya, Helena Kiefel, Kareem L. Graham, Todd Z. DeSantis, Sunit Jain, Andrew W. Han, Karim Dabbagh
-
Patent number: 12168677Abstract: The disclosure relates to therapeutic proteins and pharmaceutical compositions comprising said proteins, which have utility in treating various human diseases. In particular aspects, the disclosed therapeutic proteins are useful for treating human gastrointestinal inflammatory diseases and gastrointestinal conditions associated with decreased epithelial cell barrier function or integrity. Further, the disclosed therapeutic proteins are useful for treating human inflammatory bowel disease, including inter alia, Crohn's disease and ulcerative colitis.Type: GrantFiled: July 18, 2023Date of Patent: December 17, 2024Assignee: Genevive, Inc.Inventors: Andrew Wonhee Han, Andrew W. Goodyear, Tarunmeet Gujral, Todd Zachary DeSantis, Karim Dabbagh
-
Patent number: 12168678Abstract: The disclosure relates to engineered heme sequestering peptides and their use in treating cancer and inhibiting microbial infections and colonization.Type: GrantFiled: May 13, 2022Date of Patent: December 17, 2024Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventor: Li Zhang
-
Patent number: 12168679Abstract: The present disclosure relates generally to modified bacteria, such as E. coli, with modification in the expression of at least one gene encoding a type I and/or type II toxin-antitoxin (TA) system protein and/or at least one gene encoding a structural protein that modulates ribosomes and methods of using the disclosed bacteria for producing a biological compound of interest. The modifications of the bacteria result in enhanced bioproduction.Type: GrantFiled: November 9, 2021Date of Patent: December 17, 2024Assignee: Northwestern UniversityInventors: William H. Bothfeld, Keith E. J. Tyo
-
Patent number: 12168680Abstract: The instant invention provides soluble fusion protein complexes and IL-15 variants that have therapeutic and diagnostic use, and methods for making the proteins. The instant invention additionally provides methods of stimulating or suppressing immune responses in a mammal using the fusion protein complexes and IL-15 variants of the invention.Type: GrantFiled: April 24, 2023Date of Patent: December 17, 2024Assignee: Altor Bioscience, LLCInventors: Hing C. Wong, Peter Rhode, Xiaoyun Zhu, Kai-Ping Han
-
Patent number: 12168681Abstract: This disclosure relates to IL-2 variants and methods of use thereof, including methods of treating or inhibiting a cancer or tumor. The IL-2 variants may have reduced ability in binding to or activating IL-2R?. The IL-2 variants may retain the ability in binding to or activating IL-2R? and/or IL-2R?. In addition, the IL-2 variants may have decreased Treg activity but maintain the capacity to activate NK cells and T effector cells.Type: GrantFiled: October 25, 2023Date of Patent: December 17, 2024Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Jiaxi Wu, Tong Zhang, Samuel Davis, Nicolin Bloch
-
Patent number: 12168682Abstract: The specification describes an antibody capture process comprising (i) obtaining a biological sample comprising antibodies, (ii) contacting the biological sample with recombinant pIgR or a dIgA-binding variant, wherein the pIgR or variant binds dIgA and forms a pIgR-dIgA complex. The process may further comprise (iii) directly or indirectly assessing the level of the pIgR-dIgA complex or the level of a complex between pIgR-dIgA and an antigen of interest. There is also an antibody capture process for determining gut wall integrity in a test subject, wherein the level or ratio of SIgA to dIgA is compared to a corresponding level or ratio from a control subject. The specification provides kits embodying the process and recombinant pIgR when used for, or for use, in capturing or detecting dIgA and/or IgM.Type: GrantFiled: February 8, 2019Date of Patent: December 17, 2024Assignee: The MacFarlane Burnet Institute for Medical Research and Public Health LtdInventors: David Andrew Anderson, Mary Louise Garcia, Nadine Carmel Barnes, Khayriyyah Mohd Hanafiah, Alan Lee Landay
-
Patent number: 12168683Abstract: In certain aspects, the disclosure provides multispecific binders (e.g., ActRIIB:T?RII heteromultimers comprising an ActRIIB polypeptide and a T?RII polypeptide). In some embodiments, the disclosure provides for novel binders comprising a T?RII polypeptide and a heterologous portion. The disclosure further provides that such multispecific binders (e.g., ActRIIB:T?RII heteromultimer) may be used to treat various disorders or conditions.Type: GrantFiled: May 2, 2019Date of Patent: December 17, 2024Assignee: Acceleron Pharma Inc.Inventors: Ravindra Kumar, Dianne S. Sako, Roselyne Castonguay, Tzu-Hsing Kuo
-
Patent number: 12168684Abstract: The present invention relates to the preparation of an antibody analogue capable of being activated reversibly, and uses thereof, and provides a fusion protein comprising an inactive first fragment of an antibody analogue is fused to a stimulus-induced dimerization protein.Type: GrantFiled: September 7, 2021Date of Patent: December 17, 2024Assignee: INSTITUTE FOR BASIC SCIENCEInventors: Won Do Heo, Yun Ju Lee, Daseuli Yu, Byung Ouk Park
-
Patent number: 12168685Abstract: Isolated or recombinant EphA5 or GRP78 targeting antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer. A method of rapidly identifying antibodies or antibody fragments for the treatment of cancer using a combination of in vitro and in vivo methodologies is also provided.Type: GrantFiled: October 18, 2022Date of Patent: December 17, 2024Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEYInventors: Renata Pasqualini, Wadih Arap, Fernanda Iamassaki Staquicini, Fortunato Ferrara, Sara D'Angelo, Andrew R. M. Bradbury
-
Patent number: 12168686Abstract: Compositions of TNF family of cytokines in covalently linked trimeric forms are disclosed. The resulting fusion proteins are secreted as disulfide bond—linked homotrimers, which are more stable in structure and therapeutically more efficacious than their native counterparts.Type: GrantFiled: October 16, 2022Date of Patent: December 17, 2024Assignee: Sichuan Clover Biopharmaceuticals, Inc.Inventor: Peng Liang
-
Patent number: 12168687Abstract: Antibodies and antigen-binding fragments thereof that immunospecifically bind to PD-1, such as human or mouse PD-1, and are agonists of PD-1 and can induce or promote an immune response that activates immune cell proliferation or activity. Unlike the majority of known anti-PD-1 and anti-PD-L1 antibodies, which reduce the suppression of PD-1 function by e.g., PD-L1 by physically blocking the interaction between PD-1 and an inactivating ligand, although not to be bound by theory, the disclosed antibodies and antigen-binding fragments thereof are currently best understood to immunospecifically bind to an epitope of PD-1 whereby PD-1 is activated directly. Methods for the treatment of cancer comprising administration of the antibodies or antigen-binding fragments to a subject in need thereof. Polynucleotides encoding the antibodies or antigen-binding fragments. Host cells comprising the polynucleotides.Type: GrantFiled: January 26, 2024Date of Patent: December 17, 2024Assignee: Georgiamune Inc.Inventors: Mikayel Mkrtichyan, Samir Khleif
-
Patent number: 12168688Abstract: The present application provides an antibody, such as a monoclonal antibody (mAb), or an antigen binding fragment thereof, that specifically recognizes PD-L1. Also provided are pharmaceutical compositions, or methods of making and using the antibody or antigen binding fragment thereof.Type: GrantFiled: December 28, 2018Date of Patent: December 17, 2024Assignee: Nanjing Legend Biotech Co., Ltd.Inventors: Shuai Yang, Chuan-Chu Chou, Shu Wu, Liusong Yin, Feng Lin
-
Patent number: 12168689Abstract: An IgG1 Fc monomer, a preparation method therefor and an application thereof. Causing an Fc dimer of a novel IgG1 Fc monomer sequence for which an antibody IgG1 constant region is modified to become an Fc monomer by means of the modification on a human antibody IgG1 constant region Fc that uses antibody engineering technology, and maintaining an FcRn binding function; the present application has the feature of very low non-specific binding with unrelated proteins, and the main features of the Fc monomer comprise the T366, L368, P395, and K409 positions in a CH3 region of the constant region of the antibody having mutations, and the monomer being highly efficiently expressed in prokaryotic cells; the monomer may bind to FcRn by using a pH-dependent specific binding mode, and has the feature of very low non-specific binding.Type: GrantFiled: October 24, 2018Date of Patent: December 17, 2024Assignee: Suzhou Forlong Biotechnology Co., Ltd.Inventors: Tianlei Ying, Chunyu Wang
-
Patent number: 12168690Abstract: Provided are an anti-4-1BB/anti-EGFR bispecific antibody, and a pharmaceutical composition and a method for treating and/or preventing a cancer using the same.Type: GrantFiled: July 27, 2020Date of Patent: December 17, 2024Assignees: ABL BIO INC., YUHAN CORPORATIONInventors: Yeryoung Yong, Ui-Jung Jung, Hyejin Chung, Kyeongsu Park, Wonjun Son, Yangsoon Lee, Yeunju Kim, Eunsil Sung, Youngkwang Kim, Youngdon Pak, Minji Park, Jaehyun Eom, Hyoju Choi, Moo Young Song, Na Rae Lee, Young Bong Park, Eun-Jung Lee, Eun-Jung Lee
-
Patent number: 12168691Abstract: The present disclosure provides a bispecific antibody comprising an IgG linked to an scFv, wherein the VII domain of the IgG is linked to the VH domain of the scFv, the bispecific antibody binding a human vascular endothelial growth factor (VEGF) family protein and an epidermal growth factor receptor (EGFR) family protein. Further embodiments provide pharmaceutical compositions comprising the bispecific antibody of the embodiments and aspects thereof and a pharmaceutically acceptable carrier. Further embodiments provide various methods of treating cancer in a subject comprising administering a bispecific antibody of the embodiments and aspects thereof to the subject. A further embodiment provides a kit comprising the bispecific antibody.Type: GrantFiled: May 31, 2019Date of Patent: December 17, 2024Assignee: Board of Regents, The University of Texas SystemInventors: Zhen Fan, Yang Lu, Songho Qiu
-
Patent number: 12168692Abstract: The present disclosure relates to antibodies and antibody fragment that are specific for CCR2. The antibodies deplete CCR2-positive cells and block MCP-1 (CCL2) induced downregulation of CCR2 on human leukocytes. Furthermore, they possess advantageous biophysical properties. The antibodies are useful for the treatment of inflammatory diseases, autoimmune diseases, hematologic malignancies and potentially other illnesses.Type: GrantFiled: August 2, 2024Date of Patent: December 17, 2024Assignee: Granite Bio AGInventor: Matthias Mack
-
Patent number: 12168693Abstract: The present invention relates to treatments of conditions ameliorated by stimulation of an immune response, in particular by the stimulation of antigen-specific T-lymphocytes. Treatment of such conditions according to the invention is effected by the combination of an anti-human CD27 agonistic antibody together with a number of immune checkpoint inhibitors.Type: GrantFiled: January 16, 2019Date of Patent: December 17, 2024Assignee: ADURO BIOTECH HOLDINGS, EUROPE B.V.Inventors: Hans Van Eenennaam, Andrea Van Elsas